United Kingdom· GB-APID-38175411000001109
Virgan 0.15% eye gel
A ganciclovir product containing ganciclovir, registered in United Kingdom by DE Pharmaceuticals. The same ATC class is registered in 9 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Ganciclovir is registered in 9 of 19 countries.
Countries holding a registration under ATC S01AD09 (ganciclovir), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Ganciclovir · ATC S01AD09
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ganciclovir
- Manufacturer
- DE Pharmaceuticals
- Country
- United Kingdom (GB)
- ATC code
- S01AD09
- ATC class
- Ganciclovir
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ganciclovir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandCymeveneInPharm Sp. z o.o.
- United StatesganciclovirSagent Pharmaceuticals
- FinlandCymeveneOrifarm Oy
- SpainCYMEVENE 500 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONCheplapharm Arzneimittel Gmbh
- SwedenCymevene 500 mg Pulver till koncentrat till infusionsvätska, lösningOrifarm AB
- GermanyCymeven I.V.Cheplapharm Arzneimittel Gmbh
- CanadaCYTOVENECHEPLAPHARM ARZNEIMITTEL GMBH
- FranceCYMEVAN 500 mg, poudre pour solution à diluer pour perfusionCHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Cymevene, Ganciclovir Oresund Pharma
- Belgium · Cymevene, Virgan
- Bulgaria · Ганцикловир Ромфарм
- Czechia · Cymevene, Virgan
- Germany · Cymeven I.V., Ganciclovir Accord
- Denmark · Cymevene, Ganciclovir Oresund Pharma
- Spain · Cymevene, Ganciclovir Accord
- Finland · Cymevene, Ganciclovir Bioglan
- France · Cymevan, Ganciclovir Hikma
- Greece · Gancilen, Virgan
- Croatia · Cymevene
- Hungary · Cymevene, Ganciclovir Rompharm
- Ireland · Cymevene
- Italy · Citovirax, Ganciclovir Accord
- Luxembourg · Cymevene, Virgan
- Netherlands · Cymevene, Ganciclovir Sandoz
- Norway · Cymevene, Ganciclovir Bioglan
- Poland · Cymevene, Ganciclovir Accord
- Portugal · Cymevene, Ganciclovir Accord
- Romania · Ganciclovir Rompharm, Virgan
- Sweden · Cymevene, Ganciclovir Bioglan
- Slovakia · Cymevene
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eae3c8a2-0900-4fd7-b9b5-5ffc426247d5 GET /v1/drugs/eae3c8a2-0900-4fd7-b9b5-5ffc426247d5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38175411000001109",
"desc": "Virgan 0.15% eye gel (DE Pharmaceuticals)",
"form": "Eye gel",
"vpid": "41486411000001100",
"source": "dmd",
"vtm_id": "776081008",
"strength": "1.5 mg",
"substance": "Ganciclovir",
"ingredient": "Ganciclovir",
"supplier_code": "2268901000001109"
}See everything about ganciclovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.